With approval for China’s 2nd CAR-T therapy, Juno, WuXi joint venture goes up against Gilead and Fosun’s Yescartanews2021-09-03T14:00:34+00:00September 3rd, 2021|Fierce Pharma|
Lilly’s COVID-19 antibody combo cleared for nationwide use as feds say it can tackle the dominant delta variantnews2021-09-03T13:43:28+00:00September 3rd, 2021|Fierce Pharma|
Amid vaccine hoarding criticism, Biden admin plots $2.7 billion manufacturing pushnews2021-09-03T13:23:09+00:00September 3rd, 2021|Fierce Pharma|
Fierce Pharma Asia—Sourcing Moderna’s COVID vaccine contaminant; Astellas’ gene therapy pause; Takeda’s cancer drug flopnews2021-09-03T11:51:34+00:00September 3rd, 2021|Fierce Pharma|
First Biogen, now the FDA: Congressional Democrats request agency records about Aduhelm’s approvalnews2021-09-02T18:28:28+00:00September 2nd, 2021|Fierce Pharma|
Former Eli Lilly job applicants say the company’s hiring practices favor the youngnews2021-09-02T17:55:58+00:00September 2nd, 2021|Fierce Pharma|
After criticism, Johnson & Johnson COVID-19 vaccines shipped from South Africa to Europe to be returnednews2021-09-02T15:37:20+00:00September 2nd, 2021|Fierce Pharma|
Johnson & Johnson COVID-19 vaccines shipped from South Africa to Europe to be returnednews2021-09-02T15:37:20+00:00September 2nd, 2021|Fierce Pharma|
Swedish rare disease drugmaker Sobi to go private in $8B takeover by Advent, GICnews2021-09-02T14:46:35+00:00September 2nd, 2021|Fierce Pharma|
Behind the rebrand: AMRI swaps acronym legacy name for Curia to set stage for future growthnews2021-09-02T14:42:48+00:00September 2nd, 2021|Fierce Pharma|
